<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361111</url>
  </required_header>
  <id_info>
    <org_study_id>Dep. of Pneum. and Allerg.</org_study_id>
    <nct_id>NCT03361111</nct_id>
  </id_info>
  <brief_title>BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment</brief_title>
  <acronym>BIOSAMOT</acronym>
  <official_title>Utility of Biomarkers in Evaluating Responsiveness to Anti-IgE (Omalizumab) in Severe Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eosinophil infiltration and degranulation in airways has been implicated in the pathology of
      asthma. Periostin is considered to be a marker of eosinophilic inflammation and is one of the
      highly expressed genes in epithelial cells and lung fibroblasts in asthma. Omalizumab is
      approved as add-on therapy in the treatment of severe allergic asthma. The aim of the study
      is to assess inflammatory biomarkers including: blood and sputum eosinophilia, periostin and
      IL-6 as long-term clinical outcomes of omalizumab therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-IgE (omalizumab) has been shown to be an effective add-on therapy for patients with
      allergic severe asthma. In this observational study patients aged over 18 year with
      uncontrolled severe persistent asthma are selected for add-on therapy with omalizumab.
      Patients were on high dose of ICS and had a documented history of 2-6 exacerbations requiring
      treatment with systemic corticosteroids ( with &gt;15 mg/day prednisone or other medications at
      similar dose, for at least 3 days). The individual dose and frequency of omalizumab
      administration is assessed from the dosing table. Lung function tests and asthma
      questionnaires (ACQ, AQLQ and RQLQ) are used in the aim of assessing clinical improvement
      after omalizumab treatment. Induced sputum (IS) and exhaled breath condensate (EBC) are used
      as a simple non-invasive methods for monitoring cellular and biochemical changes in the
      airways. Total blood eosinophil count, IS cytology, IS and EBC periostin and IL-6
      concentrations are measured. Analyses are performed at entry and after 16, 52 and 104,156
      weeks of omalizumab treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2013</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 5, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in selected biomarkers in induced sputum</measure>
    <time_frame>baseline and after 156 weeks of omalizumab treament</time_frame>
    <description>eosinophil count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in selected biomarkers in peripheral blood</measure>
    <time_frame>baseline and after 156 weeks of omalizumab treament</time_frame>
    <description>eosinophil count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in selected biomarkers in induced sputum</measure>
    <time_frame>baseline and after 156 weeks of omalizumab treament</time_frame>
    <description>periostin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in selected biomarkers in exhaled breath condensate</measure>
    <time_frame>baseline and after 156 weeks of omalizumab treament</time_frame>
    <description>periostin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in selected biomarkers in induced sputum</measure>
    <time_frame>baseline and after 156 weeks of omalizumab treament</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in selected biomarkers in exhaled breath condensate</measure>
    <time_frame>baseline and after 156 weeks of omalizumab treament</time_frame>
    <description>IL-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in selected biomarkers in induced sputum</measure>
    <time_frame>baseline and after at 16,52,104 weeks of omalizumab treament</time_frame>
    <description>eosinophils, periostin, IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in selected biomarkers in exhaled breath condensate</measure>
    <time_frame>baseline and after at 16, 52, 104 weeks of omalizumab treament</time_frame>
    <description>periostin, IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in selected biomarkers in peripheral blood</measure>
    <time_frame>baseline and after at 16, 52, 104 weeks of omalizumab treament</time_frame>
    <description>eosinophil count</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lung function tests</measure>
    <time_frame>baseline and after at 16, 52, 104, 156 weeks of treament</time_frame>
    <description>FEV1, FVC, FEV1/FVC</description>
  </other_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Severe Asthma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Severe allergic asthma
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. positive history of atopy

          2. serum total IgE level between 30 and 700 IU/ml

          3. body weight not more than 150 kg

          4. high dose of ICS and LABA

          5. a documented history of 2-6 exacerbations requiring treatment with systemic
             corticosteroids ( with &gt;15 mg/day prednisone or other medications at similar dose, for
             at least 3 days).

        Exclusion Criteria:

          1. smoking

          2. pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanna Hermanowicz-Salamon, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Pulmonary Diseases and Allergy Medical University of Warsaw, Poland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Hermanowicz-Salamon, MD, PhD</last_name>
    <phone>+ 48 225992599</phone>
    <email>jhermanowiczsalamon@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rafał Krenke, MD, PhD, Prof</last_name>
    <phone>+48 225992562</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Joanna Hermanowicz-Salamon</name>
      <address>
        <city>Warsaw</city>
        <zip>00-707</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Hermanowicz-Salamon, MD PhD</last_name>
      <phone>606635722</phone>
      <email>jhermanowiczsalamon@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <results_reference>
    <citation>Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. 2011 Jan;139(1):28-35. doi: 10.1378/chest.10-1194. Epub 2010 Aug 5. Review.</citation>
    <PMID>20688929</PMID>
  </results_reference>
  <results_reference>
    <citation>Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11. doi: 10.1164/rccm.201208-1414OC.</citation>
    <PMID>23471469</PMID>
  </results_reference>
  <results_reference>
    <citation>ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001 Sep 1;164(5):744-8.</citation>
    <PMID>11549526</PMID>
  </results_reference>
  <results_reference>
    <citation>Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002 Nov 30;360(9347):1715-21.</citation>
    <PMID>12480423</PMID>
  </results_reference>
  <results_reference>
    <citation>Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol. 2012 Sep;130(3):647-654.e10. doi: 10.1016/j.jaci.2012.06.025. Epub 2012 Aug 1.</citation>
    <PMID>22857879</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Warsaw</investigator_affiliation>
    <investigator_full_name>Joanna Hermanowicz-Salamon</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>severe asthma</keyword>
  <keyword>anti-IgE</keyword>
  <keyword>periostin</keyword>
  <keyword>induced sputum,</keyword>
  <keyword>exhaled breath condensate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

